Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives $30.83 Consensus PT from Analysts

Key Points

• Tyra Biosciences, Inc. has received a consensus rating of "Buy" from six research firms, with an average 12-month price target of $30.83.
• The stock is currently valued at $10.20 after a decline of 5.6%, showing a substantial difference from its 52-week high of $29.60.
• Insiders have sold 61,392 shares of the company in the last three months, which reflects a 15.20% ownership stake from insiders.

Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) has been assigned an average recommendation of "Buy" from the six analysts that are currently covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $30.8333.

TYRA has been the topic of a number of recent research reports. Piper Sandler initiated coverage on Tyra Biosciences in a research note on Wednesday, May 21st. They set an "overweight" rating and a $33.00 price objective on the stock. HC Wainwright reissued a "buy" rating and set a $30.00 price objective on shares of Tyra Biosciences in a research note on Tuesday, July 1st.

Insider Activity at Tyra Biosciences

In other news, Director Gilla Kaplan sold 30,000 shares of the company's stock in a transaction on Thursday, June 12th. The stock was sold at an average price of $10.31, for a total value of $309,300.00. Following the transaction, the director owned 59,623 shares of the company's stock, valued at $614,713.13. This represents a 33.47% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last quarter, insiders sold 61,392 shares of company stock valued at $628,358. Corporate insiders own 15.20% of the company's stock.

Hedge Funds Weigh In On Tyra Biosciences

Several large investors have recently modified their holdings of the business. US Bancorp DE raised its holdings in shares of Tyra Biosciences by 50.5% in the 1st quarter. US Bancorp DE now owns 5,435 shares of the company's stock valued at $51,000 after buying an additional 1,823 shares during the period. BNP Paribas Financial Markets purchased a new stake in shares of Tyra Biosciences in the 4th quarter valued at $60,000. Aquatic Capital Management LLC purchased a new stake in shares of Tyra Biosciences in the 4th quarter valued at $64,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Tyra Biosciences in the 1st quarter valued at $84,000. Finally, Exchange Traded Concepts LLC raised its holdings in shares of Tyra Biosciences by 42.7% in the 1st quarter. Exchange Traded Concepts LLC now owns 11,861 shares of the company's stock valued at $110,000 after buying an additional 3,550 shares during the period. Institutional investors and hedge funds own 84.14% of the company's stock.

Tyra Biosciences Price Performance

Shares of Tyra Biosciences stock traded up $1.46 during mid-day trading on Wednesday, reaching $11.70. 418,585 shares of the stock traded hands, compared to its average volume of 193,896. Tyra Biosciences has a fifty-two week low of $6.42 and a fifty-two week high of $29.60. The business has a 50-day moving average of $10.35 and a 200 day moving average of $10.33.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last issued its earnings results on Thursday, August 14th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.06. As a group, analysts predict that Tyra Biosciences will post -1.57 EPS for the current fiscal year.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.